跳至主要内容
临床试验/NCT01433042
NCT01433042已完成不适用

Assessment the Performance of PillCam SB3 Capsule in Detecting Small Bowel Lesions in Patients

Medtronic - MITG4 个研究点 分布在 4 个国家目标入组 225 人开始时间: 2011年8月1日最近更新:
适应症
干预措施

试验速览

阶段
不适用
状态
已完成
入组人数
225
试验地点
4
主要终点
Precentage of SB3 Images That Were Graded as Superior in Image Quality to SB2 by the Physicians

研究概览

简要总结

Study hypothesis: PillCam SB3 is a new capsule designed to provide an improved image quality, and improved SB and duodenum tissue coverage due to Adaptive Frame Rate (AFR) of 2-6 fps, which will create more images for evaluation, and therefore should improve diagnostic accuracy.

Proposed Design: to enroll up to 230 patients with symptoms suggesting the presence of small bowel disease.

Preparation for procedure will include 12 hours fasting prior to the capsule ingestion

Patients will undergo a standard capsule endoscopy. Patients will be allowed to drink clear liquids 2 hours post ingestion, and eat 4 hours post ingestion.

Diagnostic yield of the SB3 will be calculated The Physician's subjective assessment of capsule performance will be captured

详细描述

  • Purpose of study- To assess the performance of PillCam SB3 capsule in detecting small bowel lesions in patients
  • Study design- Feasibility study
  • Number of subjects- Up to 200
  • Subject population- Patients with symptoms suggestive of small bowel disease and whom are eligible and indicated for SB capsule endoscopy
  • No of centers- 4
  • Duration of enrollment up to 12 months from IRB approval to enroll study patients
  • Duration of follow-up 1 week after capsule procedure.
  • Primary objectives To evaluate the performance of SB-3 system in patients as per physician questionnaire

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Diagnostic
盲法
None

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者
否

入选标准

  • •Patient age is ≥ 18 years old,
  • •Patients with history suggestive and /OR symptoms suggestive of small bowel disease and whom are eligible and indicated for SB capsule endoscopy,
  • •Patient and/or legal guardian is able and agrees to sign the Informed Consent Form

排除标准

  • •Patient has dysphagia,
  • •Patient is known or is suspected to suffer from intestinal obstruction,
  • •Patient has known previous stricture/obstruction of the SB or colon,
  • •Patient has a cardiac pacemakers or other implanted electro medical devices,
  • •Women who are either pregnant or nursing at the time of screening, who intend to be during the study period, or are of child-bearing potential and do not practice medically acceptable methods of contraception,
  • •Patient is expected to undergo MRI examination within 7 days after ingestion of the capsule,
  • •Patient has had prior abdominal surgery of the gastrointestinal tract other than uncomplicated procedures that would be unlikely to lead to bowel obstruction based on the clinical judgment of the investigator,
  • •Patient has any condition, which precludes compliance with study and/or device instructions,
  • •Patient suffers from life threatening conditions,
  • •Patient is currently participating in another clinical study,
  • •Patient has known slow gastric emptying time

研究组 & 干预措施

capsule endoscopy

Experimental

干预措施: capsule endoscopy (Device)

结局指标

主要结局

Precentage of SB3 Images That Were Graded as Superior in Image Quality to SB2 by the Physicians

时间窗: up to 6 months from end of recruitment

precentage of SB3 images that were graded as superior in image quality to SB2 by the physicians

次要结局

未报告次要终点

研究者

申办方类型
Industry
责任方
Sponsor

研究点 (4)

Loading locations...

相似试验

PillCam SB3 Capsule- Feasibility Study | 临床试验